Table 2.

Outcomes and toxicities with RVD combination regimens as induction therapy

Outcomes and toxicities with RVD combination regimens as induction therapy
Outcomes and toxicities with RVD combination regimens as induction therapy

RVD indicates lenalidomide, bortezomib, and dexamethasone; D, pegylated doxorubicin; C, cyclophosphamide; P, panobinostat; V, vorinostat; PR, partial response; VGPR, very good partial response; CR, complete response; nCR, near complete response; PFS, progression-free survival; and NR, not reported.